Is Avis Budget Group, Inc. (CAR) a Buy, Sell, or Hold?
NASDAQ : CAR
Avis Budget Group, Inc.
$158.945 USD
$2.6 (1.66%)
- Volume
- 49.36K
- Average Volume
- 2.2M
- Market Capitalization
- $5.61B
- P/E Ratio
- -8.40
- Dividend Yield
- 0.00%
- Price Target
- $132.50
- Year High
- $847.70
- Year Low
- $85.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.74
Company Overview
NASDAQ
Brian J. Choi
Rental & Leasing Services
Industrials
CAR
25000
US
USD
Liquidity Metrics
-8.10
0.74
0.74
0.18
0.00
Sales & Valuation
$11.65B
0.48
-1.64
-3.66
-43.40
Profitability
-$25.26
-$889M
-5.68%
-5.04%
22.83%
-2.18%
P/E Metrics
-8.40
-0.08
-0.08
Analyst Price Target & Rating
$132.50
$160.00
$85.00
2/5
13 Analysts
19.96%
Poll Results
About Avis Budget Group, Inc. (NASDAQ:CAR) Stock
Avis Budget Group, Inc. is a prominent global provider of diverse mobility solutions, delivering vehicle rental services for both cars and trucks, alongside car-sharing options, to a broad clientele encompassing businesses and individual consumers. The company's brand portfolio includes Avis, which focuses on providing premium vehicle rentals and comprehensive mobility solutions to both commercial and leisure segments of the travel industry. For truck and cargo van rentals, the Budget Truck brand operates a fleet of approximately 20,000 vehicles. These are available for local and one-way hire through a vast network of roughly 465 dealer-operated and 385 company-owned locations across the continental United States, catering to both residential and light commercial needs. Furthermore, the co ... mpany manages Zipcar, a well-known car-sharing network, and an array of other car rental brands such as Budget, Payless, Apex, Maggiore, MoriniRent, FranceCars, Amicoblue, Turiscar, and ACL Hire. Beyond its core vehicle offerings, Avis Budget Group supplies an extensive range of supplementary products and services. These include various optional insurance covers, such as supplemental liability, personal accident, personal effects protection, emergency sickness, and insurance for automobile towing and cargo. Customers can also access fuel service plans, roadside assistance, electronic toll collection, curbside delivery, and rentals for items like tablets, satellite radio access, portable navigation units, and child safety seats. For moving purposes, the company provides automobile towing equipment and essential accessories such as hand trucks, furniture pads, and moving supplies. Additionally, corporate clients benefit from a Business Intelligence solution, an online platform designed for managing their corporate travel needs. With a significant international presence, Avis Budget Group, Inc. operates at approximately 10,400 locations across the globe. Founded in 1946 and headquartered in Parsippany, New Jersey, the company was formerly named Cendant Corporation before adopting its current name in September 2006.
2026-07-15 07:00:00
BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor T-cell (“CAR-T”) product candidates, today announced details of its next-generation in vivo CAR-T platform. The company plans to advance TPST-4003, its lead in vivo CAR-T product candidate, into a first investigator-initiated clinical trial in patients with nervous system autoimmune diseases, initially focusing on myasthenia gravis (“MG”) and multiple sclerosis (“MS”). The study is expected to enroll approximately 10 patients, with first patient dosing anticipated in the fourth quarter of 2026.
Avis Budget Group to Announce Second Quarter 2026 Results on July 28, 2026
2026-07-13 17:32:00
PARSIPPANY, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its second quarter 2026 financial results after the market close on Tuesday, July 28, 2026, and to host a conference call for institutional investors to discuss these results on Wednesday, July 29, 2026, at 8:30 a.m.
2026-07-13 09:00:00
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company,
2026-07-06 08:30:00
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company's off-the-shelf CAR T-cell product candidate, FT819, will be presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, being held at the Palais des congrès de Montréal in Montréal, Canada on July 8 - 11, 2026.
2026-07-06 08:30:00
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., July 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer.
Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS
2026-07-06 07:15:59
Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. Recent regulatory alignment enables a rolling BLA submission for SPS, with pivotal single-arm Phase 2 data showing strong efficacy and safety, targeting FDA approval by late 2026. KYTX maintains a cash runway through 2028, supported by $236M in cash and a $150M credit facility, enabling completion of key trials and commercial launch preparation.
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
2026-07-04 10:10:17
Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329's early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering.
Strong Car Rental Demand Aids Avis Budget Group Amid Low Liquidity
2026-07-03 10:36:06
CAR gains from rising demand for short-term vehicle rentals, but geopolitical risks, low liquidity and lack of dividend cloud its long-term outlook.
Frequently Asked Questions
-
What is the current Avis Budget Group, Inc. (CAR) stock price?
-
Avis Budget Group, Inc.(NASDAQ:CAR) stock price is $158.945 in the last trading session. During the trading session, CAR stock reached the peak price of $847.7 while $85.96 was the lowest point it dropped to. The percentage change in CAR stock occurred in the recent session was 1.66% while the dollar amount for the price change in CAR stock was $2.6.
-
CAR's industry and sector of operation?
-
The NASDAQ listed CAR is part of Rental & Leasing Services industry that operates in the broader Industrials sector.
-
Who are the executives of CAR?
-
Stephen Wright | Senior Vice President of Global Travel, Partnerships & Government
Brian J. Choi | Chief Executive Officer
Edward Linnen | Chief Human Resource Officer & Executive Vice President
Cathleen DeGenova | Adviser
Anna Maria Pawlak Kuliga | President of International -
How many employees does CAR have?
-
Number of CAR employees currently stands at 25000. CAR operates from 379 Interpace Parkway, Parsippany, NJ 07054, US.
-
Link for CAR official website?
-
Official Website of CAR is: https://www.avisbudgetgroup.com
-
How do I contact CAR?
-
CAR could be contacted at phone #973 496 4700 and can also be accessed through its website. CAR operates from 379 Interpace Parkway, Parsippany, NJ 07054, US.
-
How many shares of CAR are traded daily?
-
The average number of CAR shares traded daily for last 3 months was 2.2M.
-
What is the market cap of CAR currently?
-
The market value of CAR currently stands at $5.61B with its latest stock price at $158.945